Search 

Cypralis was spun out from Selcia Ltd (Ongar, Essex) in 2013 to exploit its extensive expertise and know-how in targeting peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets involved in many acute and chronic diseases. Cypralis is dedicated to the discovery and development of innovative therapeutics for the inhibition of PPIases and expects to build upon its existing intellectual property estate through its own R&D activities and also through risk-sharing collaborations with pharmaceutical companies.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.

At Invisio we are creating innovative medicines helping to transform peoples’ lives, developing partnerships, working alongside organisations to ensure best care solutions are available as broadly as possible. Modern medicine involves tailoring the right therapy for the patient to ensure best results. We offer customers Pharmacogenetic Testing, an Adherence Monitoring App, and two oral liquid versions of medications for motor and non-motor symptoms of Parkinson's Disease, Stroke, MS, ALS and TBI.